Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Sean WhartonSalvatore CalannaMelanie Jane DaviesDror DickerBryan GoldmanIldiko LingvayLawrence A LeiterDomenica M RubinoMette ThomsenThomas A WaddenSue D PedersenPublished in: Diabetes, obesity & metabolism (2021)
GI AEs were more common with semaglutide 2.4 mg than placebo, but typically mild-to-moderate and transient. Semaglutide-induced WL was largely independent of GI AEs.
Keyphrases
- weight loss
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- weight gain
- diabetic rats
- high glucose
- glycemic control
- metabolic syndrome
- type diabetes
- obese patients
- insulin resistance
- drug induced
- placebo controlled
- body mass index
- endothelial cells
- study protocol
- subarachnoid hemorrhage
- stress induced
- adipose tissue